Analyst Reco. Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:02 2024-05-02 pm EDT			Pre-market 07:47:06 am
43.7 ^USD	-1.15%		43.79	+0.21%

May. 01	HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	MT
May. 01	Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	May. 01	MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	Apr. 30
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60	Apr. 29	MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating	Apr. 29	MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	Apr. 26	MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating	Apr. 26	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51	Apr. 26	MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65	Apr. 26	MT
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40	Apr. 26	MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating	Apr. 26	MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55	Apr. 26	MT
Jefferies Adjusts Bristol-Myers Squibb Price Target to $54 From $56, Keeps Hold Rating	Apr. 25	MT
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating	Apr. 25	MT
Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating	Apr. 22	MT
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating	Apr. 18	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept	Apr. 15	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating	Apr. 15	MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58	Apr. 12	MT
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating	Apr. 09	MT
Societe Generale Downgrades Bristol-Myers Squibb to Hold From Buy, Cuts Price Target to $51 From $85	Mar. 11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST